Haisco Pharmaceutical Hits Day High with 10% Surge in Stock Price

Haisco Pharmaceutical Group Co., Ltd. has experienced a significant surge in its stock performance, gaining 10.0% on June 29, 2026. The stock reached an intraday high of CNY 61.06, reflecting strong market activity. Over the past week, Haisco has shown impressive growth, with a 24.03% increase, significantly outperforming the China Shanghai Composite, which declined by 2.14% during the same period. In terms of longer-term performance, Haisco has demonstrated robust growth metrics, including a remarkable 44.11% increase over the past year and a staggering 164.33% rise over the last three years. The company's financial health is underscored by a high operating cash flow of CNY 1,126.55 million and a return on capital employed (ROCE) of 17.13%. Additionally, the decline in raw material costs by 19.75% year-over-year has positively impacted profitability. Despite its high valuation, with a price-to-book ratio of 5.14 and a return on equity of 15.84%, Haisco continues to deliver consistent returns, making it a noteworthy player in the pharmaceuticals and biotechnology sector.